Multiple sclerosis (Houndmills, Basingstoke, England) · 2025
Human papillomavirus-related conditions in women with multiple sclerosis receiving disease-modifying therapies: A Pharmacovigilance disproportionality analysis from the WHO vigibase®.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bordet Constance, Maachi Oumaïma, Papeix Anne-Caroline, Laigo Pauline, Thomas Laure, Grimaldi Lamiae
Аннотация
BACKGROUND: High-efficacy multiple sclerosis disease-modifying therapies (MS-DMTs) are associated with heightened immunosuppressive effects, potentially increasing the risk of infections. However, their association with human papillomavirus (HPV)-related conditions remains underexplored, particularly for newer treatments.
OBJECTIVE: To evaluate a signal of disproportionate reporting HPV-related conditions in women with MS-DMTs using real-world pharmacovigilance data.
METHODS: Individual case safety reports (ICSRs) from Vigibase®, the WHO global pharmacovigilance database, were analysed for MS-DMTs from 1 January 2000 to 31 December 2023. Disproportionality analysis was performed to calculate adjusted reporting odds ratios (aRORs) and Bayesian information component (IC) with 95% confidence intervals (95% CIs), for HPV-related conditions associated with each MS-DMT.
RESULTS: Among 418,182 ICSRs involving MS-DMTs, 1111 reported HPV-related conditions. Fingolimod showed the highest aROR of 3.50 (95% CIs = 2.95-4.16), followed by ocrelizumab (2.48 (1.83-3.31)) and natalizumab (1.63 (1.34-1.97)) compared to pegylated or non-pegylated interferon betas.
DISCUSSION: This study identified a potential signal of disproportionate reporting of HPV-related conditions with fingolimod, ocrelizumab and natalizumab based on real-world pharmacovigilance data. These exploratory findings highlight the need for population-based pharmacoepidemiological studies to confirm the signal, while HPV vaccination and cancer screening remain key preventive measures for patients on MS-DMTs.
OBJECTIVE: To evaluate a signal of disproportionate reporting HPV-related conditions in women with MS-DMTs using real-world pharmacovigilance data.
METHODS: Individual case safety reports (ICSRs) from Vigibase®, the WHO global pharmacovigilance database, were analysed for MS-DMTs from 1 January 2000 to 31 December 2023. Disproportionality analysis was performed to calculate adjusted reporting odds ratios (aRORs) and Bayesian information component (IC) with 95% confidence intervals (95% CIs), for HPV-related conditions associated with each MS-DMT.
RESULTS: Among 418,182 ICSRs involving MS-DMTs, 1111 reported HPV-related conditions. Fingolimod showed the highest aROR of 3.50 (95% CIs = 2.95-4.16), followed by ocrelizumab (2.48 (1.83-3.31)) and natalizumab (1.63 (1.34-1.97)) compared to pegylated or non-pegylated interferon betas.
DISCUSSION: This study identified a potential signal of disproportionate reporting of HPV-related conditions with fingolimod, ocrelizumab and natalizumab based on real-world pharmacovigilance data. These exploratory findings highlight the need for population-based pharmacoepidemiological studies to confirm the signal, while HPV vaccination and cancer screening remain key preventive measures for patients on MS-DMTs.